Characterization of Large Immune Complexes with Size Exclusion Chromatography and Native Mass Spectrometry Supplemented with Gas Phase Ion Chemistry.

Large immune complexes formed by the cross-linking of antibodies with polyvalent antigens play critical roles in modulating cell-mediated immunity. While both the size and the shape of immune complexes are important determinants in Fc receptor-mediated signaling responsible for phagocytosis, degranulation, and, in some instances, autoimmune pathologies, their characterization remains extremely challenging due to their large size and structural heterogeneity. We use native mass spectrometry (MS) supplemented with limited charge reduction in the gas phase to determine the stoichiometry of immune complexes formed by a bivalent (homodimeric) antigen, a 163 kDa aminopeptidase P2 (APP2), and a monoclonal antibody (mAb) to APP2. The observed (APP2·mAb)n complexes populate a wide range of stoichiometries (n = 1-4) with the largest detected species exceeding 1 MDa, although the gas-phase dissociation products are also evident in the mass spectra. While frequently considering a nuisance that complicates interpretation of native MS data, limited dissociation provides an additional dimension for characterization of the immune complex quaternary structure. APP2/mAb associations with identical composition but slightly different elution times in size exclusion chromatography exhibit notable differences in their spontaneous fragmentation profiles. The latter indicates the presence of both extended linear and cyclized (APP2·mAb)n configurations. The unique ability of MS to distinguish between such isomeric structures will be invaluable for a variety of applications where the biological effects of immune complexes are determined by their ability to assemble Fc receptor clusters of certain density on cell surfaces, such as platelet activation by clustering the low-affinity receptors FcγRIIa on their surface.

Targeting caveolae to pump bispecific antibody to TGF-ß into diseased lungs enables ultra-low dose therapeutic efficacy.

The long-sought-after "magic bullet" in systemic therapy remains unrealized for disease targets existing inside most tissues, theoretically because vascular endothelium impedes passive tissue entry and full target engagement. We engineered the first "dual precision" bispecific antibody with one arm pair to precisely bind to lung endothelium and drive active delivery and the other to precisely block TGF-ß effector function inside lung tissue. Targeting caveolae for transendothelial pumping proved essential for delivering most of the injected intravenous dose precisely into lungs within one hour and for enhancing therapeutic potency by >1000-fold in a rat pneumonitis model. Ultra-low doses (µg/kg) inhibited inflammatory cell infiltration, edema, lung tissue damage, disease biomarker expression and TGF-ß signaling. The prodigious benefit of active vs passive transvascular delivery of a precision therapeutic unveils a new promising drug design, delivery and therapy paradigm ripe for expansion and clinical testing.

Assuring Quality of Dietary Supplements for Cancer Patients: An Integrative Formulary Systems Approach.

CONTEXT: The quality of dietary supplements is highly variable and, therefore, may pose unique risks to cancer patients, who increasingly use these products. Although they are highly regulated, the US Food and Drug Administration (FDA) has reported extensive noncompliance with current Good Manufacturing Practices (cGMPs), which further heightens concerns. OBJECTIVE: The study intended to investigate the dietary supplements quality practices of current and prospective suppliers of supplements. DESIGN: Thirteen manufacturers, marketing 19 dietary supplement brands, were selected for inclusion, and 9 participated. SETTING: This study took place at and was supported by the Cancer Treatment Centers of America (Boca Raton, FL, USA). OUTCOME MEASURES: To ensure patients' safety, the research team established a dietary supplement formulary committee at the Cancer Treatment Centers of America. A proprietary survey tool was used to measure clinically critical quality markers and compliance with FDA regulations. Information was obtained from suppliers via nondisclosure agreements. Manufacturing documents were audited and compared with responses to the survey. The FDA's audit reports were obtained by request under the Freedom of Information Act. Several site audits were conducted, and third-party analytical testing was performed as needed. RESULTS: Although all companies claimed full compliance with cGMPs as of the survey's date, (1) 3 had received warning letters from the FDA for GMP violations, (2) 2 had recalled a product within the preceding 5 y, (3) 4 had reported products that failed independent testing for potency and purity, (4) 1 did not have product specifications, (5) 1 was found by the FDA to have inadequate testing, (6) 1 was found to have a lack of sufficient controls throughout the supply chain to guard against microbial contamination, and (7) 2 had confirmed melamine contamination or lack of melamine testing for protein powders. CONCLUSIONS: These findings confirm the concern of variable dietary supplement quality and describe a rational process others can use to assess products' quality and ensure patients' safety. Although the current study focused on practitioners' branded products used in an oncology setting, the results are relevant to the use of all dietary supplements in both oncological and nononcological settings.

Tumor targeting, trifunctional dendritic wedge.

We report in vitro and in vivo evaluation of a newly designed trifunctional theranostic agent for targeting solid tumors. This agent combines a dendritic wedge with high boron content for boron neutron capture therapy or boron MRI, a monomethine cyanine dye for visible-light fluorescent imaging, and an integrin ligand for efficient tumor targeting. We report photophysical properties of the new agent, its cellular uptake and in vitro targeting properties. Using live animal imaging and intravital microscopy (IVM) techniques, we observed a rapid accumulation of the agent and its retention for a prolonged period of time (up to 7 days) in fully established animal models of human melanoma and murine mammary adenocarcinoma. This macromolecular theranostic agent can be used for targeted delivery of high boron load into solid tumors for future applications in boron neutron capture therapy.

Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex.

Hypoxia is a hallmark of solid tumors, is associated with local invasion, metastatic spread, resistance to chemo- and radiotherapy, and is an independent, negative prognostic factor for a diverse range of malignant neoplasms. The cellular response to hypoxia is primarily mediated by a family of transcription factors, among which hypoxia-inducible factor 1 (HIF1) plays a major role. Under normoxia, the oxygen-sensitive α subunit of HIF1 is rapidly and constitutively degraded but is stabilized and accumulates under hypoxia. Upon nuclear translocation, HIF1 controls the expression of over 100 genes involved in angiogenesis, altered energy metabolism, antiapoptotic, and pro-proliferative mechanisms that promote tumor growth. A designed transcriptional antagonist, dimeric epidithiodiketopiperazine (ETP 2), selectively disrupts the interaction of HIF1α with p300/CBP coactivators and downregulates the expression of hypoxia-inducible genes. ETP 2 was synthesized via a novel homo-oxidative coupling of the aliphatic primary carbons of the dithioacetal precursor. It effectively inhibits HIF1-induced activation of VEGFA, LOX, Glut1, and c-Met genes in a panel of cell lines representing breast and lung cancers. We observed an outstanding antitumor efficacy of both (±)-ETP 2 and meso-ETP 2 in a fully established breast carcinoma model by intravital microscopy. Treatment with either form of ETP 2 (1 mg/kg) resulted in a rapid regression of tumor growth that lasted for up to 14 days. These results suggest that inhibition of HIF1 transcriptional activity by designed dimeric ETPs could offer an innovative approach to cancer therapy with the potential to overcome hypoxia-induced tumor growth and resistance.

Coupling between substituents as a function of cage structure: synthesis and valence ionized states of bridgehead disubstituted parent and hexafluorinated bicyclo[1.1.1]pentane derivatives C5X6Y2.

He(I) photoelectron spectroscopy was used to examine the valence-shell electronic structure of three new and seven previously known bicyclo[1.1.1]pentane derivatives, 1,3-Y2-C5X6 (for X = H, Y = H, Cl, Br, I, CN; for X = F, Y = H, Br, I, CN). A larger series (X = H or F, Y = H, F, Cl, Br, I, At, CN) has been studied computationally with the SAC-CI (symmetry-adapted cluster configuration interaction) method. The outer-valence ionization spectra calculated by the SAC-CI method, including spin-orbit interaction, reproduced the experimental photoelectron spectra well, and quantitative assignments are given. When the extent of effective through-cage interaction between the bridgehead halogen lone-pair orbitals was defined in the usual way by orbital-energy splitting, it was found to be larger than that mediated by other cages such as cubane, and was further enhanced by hexafluorination. The origin of the orbital-energy splitting is analyzed in terms of cage structure, and it is pointed out that its relation to the degree of interaction between the bridgehead substituents is not as simple as is often assumed.

Cycloaddition of delta2-thiazolines and acyl ketenes under acidic conditions results in bicyclic 1,3-oxazinones and not 6-acylpenams as earlier reported.

[reaction: see text] Optically active Delta(2)-thiazolines 4 were previously reported to react with acyl Meldrum's acid derivatives 5 under acidic conditions (HCl (g) in benzene) to stereoselectively give 6-acylpenams 1. Recently we have discovered that the structure elucidation of these compounds was incorrect. Thus, we report new data showing that instead of acyl beta-lactams, the optically active isomers 3R,9R-1,3-oxazinones 3a-g are obtained stereoselectively in 38-93% yields.

Manifestations of Bridgehead-Bridgehead Interactions in the Bicyclo[1.1.1]pentane Ring System.

A series of 3-halo-substituted bicyclo[1.1.1]pentane-1-carboxylic acids 1 (Y = COOH; X = F, Cl, Br, I, and CF(3)) as well as the parent compound 1 (Y = COOH, X = H) have been prepared, and a study of some of their properties have been made. It was found that their reactions with xenon difluoride cover a wide range of reactivities. On one hand, the fluoro acid 1 (Y = COOH, X = F) displayed no apparent reaction at all while, on the other, the bromo acid 1 (Y = COOH, X = Br) and parent compound 1 (Y = COOH, X = H) underwent ready reaction with complete disintegration of the ring system. A possible explanation is advanced based on polar kinetic and thermodynamic effects governing the lifetime of an intermediate acyloxy radical species. The relative ease of oxidation of the carboxylates 1 (Y = COO(-); X = H, F, Cl, Br, I, CF(3), and COOCH(3)), as mirrored by their peak oxidation potential values (E(p)) determined by cyclic voltammetry, also covers a wide range. These data coupled with the dissociation constants (pK(a)) of some of the acids 1 (Y = COOH; X = H, F, Cl, and CF(3)) reflect significantly on the modes of transmission of electronic effects acting through the bicyclo[1.1.1]pentane ring system.